PRGO — Perrigo Company plc stock price, charts and financials

QT42Perrigo Company plc

Perrigo Company plc (NYSE: PRGO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
12.52
-0.32-2.53%
PRGOQT42Perrigo Company plc·NYSE
12.52-2.53%
News
Down 2.5% — Are Investors Undervaluing Perrigo (PRGO) Right Now? (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-13.11Insider Own1.22%Shs Outstand138.37MPerf Week27.00%
Market Cap1.78BForward P/E5.35EPS next Y2.40Insider Trans0.00%Shs Float137.77MPerf Month23.34%
Enterprise Value4.67BPEG0.00EPS next Q-Inst Own-Short Float16.65%Perf Quarter9.56%
Income-1.73BP/S0.43EPS this Y116.79%Inst Trans-Short Ratio7.22Perf Half Y-10.02%
Sales4.14BP/B0.71EPS next Y9.08%ROA-22.80%Short Interest22.93MPerf YTD-7.76%
Book/sh-P/C7.09EPS next 5Y7.14%ROE-55.97%52W High23.99 -47.83%Perf Year-45.62%
Cash/sh-P/FCF10.15EPS past 3/5Y-ROIC3.27%52W Low9.00 39.11%Perf 3Y-64.63%
Dividend Est.1.16 (9.27%)EV/EBITDA-Sales past 3/5Y-1.51% 0.79%Gross Margin33.26%Volatility5.76% 4.67%Perf 5Y-73.27%
Dividend TTM1.16 (9.27%)EV/Sales1.13EPS Y/Y TTM-948.80%Oper. Margin5.19%ATR (14)0.66Perf 10Y-85.90%
Dividend Ex-DateAug 28, 2026Quick Ratio1.32Sales Y/Y TTM-4.46%Profit Margin-41.85%RSI (14)67.95Recom2.64
Dividend Gr. 3/5Y3.71% 5.21%Current Ratio2.32EPS Q/Q-28.33%SMA2019.32%Beta0.58Target Price36.20
Payout-11.52%Debt/Eq1.31Sales Q/Q-7.18%SMA5020.63%Rel Volume0.61Prev Close12.84
Employees8,100LT Debt/Eq1.33EarningsNov 04SMA2001.71%Avg Volume3.44MPrice12.52
IPO DateDec 17, 1991Option/ShortYes / YesEPS/Sales Surpr.40.17% -6.38%Net Debt/EBITDA-2.36Volume2,107,035Change-2.53%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-06-25ReiteratedCanaccord GenuityBuy$40$20
Nov-06-25DowngradeJP MorganOverweightNeutral
Oct-27-25ReiteratedJefferiesHold$30$23
Aug-07-25ReiteratedCanaccord GenuityBuy$40
Jan-14-25DowngradeArgusBuyHold
Jan-06-25DowngradePiper SandlerOverweightNeutral
Sep-23-24DowngradeJefferiesBuyHold$30
Jun-13-24ReiteratedPiper SandlerOverweight$39$36
Apr-08-24ReiteratedPiper SandlerOverweight$37$39
Nov-17-23InitiatedPiper Sandler$37
Latest News
Today
Aug-08-26
Aug-08-2609:04PM
Aug-06-26
Aug-05-26
Jul-30-26
Jul-30-2608:30AM
Jul-29-26
Jul-22-26
Jul-14-26
Jun-30-26
Jun-25-26
Jun-15-26
Jun-12-26
Company

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue4,1454,2534,373
Cost of Goods Sold Incl. D&A2,7662,7592,831
Gross Profit1,3791,4951,543
Selling, General and Administrative Excl. Other3335271,113
Research and Development9695112
Other Operating Expense737529205
Operating Income216343113
Interest Expense163163188
Unusual Expense
Non-Operating Income (Expense)-1,664-1,479-6
Net Income Before Taxes-1,613-1,298-81
Income Taxes9110480
Consolidated Net Income-1,734-1,425-172
Net Income From Continuing Operations-1,702-1,402-161
Net Income-1,734-1,425-172
EPS (Recurring)-12.51-10.29-1.25
EPS (Basic, Before Extraordinaries)-12.51-10.29-1.25
EPS (Diluted)-12.52-10.29-1.25
EBITDA-1,224-798433
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio0.420.450.81
Gross Margin33.2735.1535.28
Operating Margin5.218.062.58
Net Margin-41.83-33.51-3.93
Shares Outstanding139139137
Market Capitalization1,7401,9353,522
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$31.31$25.07$18.84$12.61$6.37 Close Price0.00K101.21K202.41K303.62K404.82KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Winterman Matthew JohnEVP, Supply, Ops, StrategyJul 08 '26Option Exercise10.5217,503184,13115,660Jul 09
Khoury RobertoEVP and President of CSCIJul 08 '26Option Exercise10.527377,75314,498Jul 09
Parker Geoffrey M.DirectorJun 12 '26Option Exercise10.9997610,72633,686Jun 16
Alford Bradley ADirectorJun 12 '26Option Exercise10.9997610,72645,934Jun 16
Lockwood-Taylor Patrickother: Former CEO and directorJun 05 '26Option Exercise10.8325,230273,241136,076Jun 09
Khoury RobertoEVP and President of CSCIJun 05 '26Option Exercise10.8317,902193,87817,433Jun 08
Willis RobertEVP & CHROJun 05 '26Option Exercise10.833,44137,26652,365Jun 08
Lennox AbigailEVP and CSOJun 05 '26Option Exercise10.833,82341,4036,603Jun 08
Bezerra Eduardo GuaritaEVP & Chief Financial OfficerJun 05 '26Option Exercise10.839,17599,36586,935Jun 08
Ball DavidEVP & CBDOJun 05 '26Option Exercise10.832,86731,0507,784Jun 08
Atkinson CharlesEVP, General Counsel & Sec.Jun 05 '26Option Exercise10.836,69072,4537,690Jun 08
O'Connor DonalDirectorMay 14 '26Option Exercise10.847,30579,18637,942May 15
Parker Geoffrey M.DirectorMay 14 '26Option Exercise10.847,30579,18636,217May 15
Brown Julia MDirectorMay 14 '26Option Exercise10.847,30579,18615,339May 15
Manzone AlbertDirectorMay 14 '26Option Exercise10.847,30579,18619,860May 15
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.